Document Detail

TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
MedLine Citation:
PMID:  17270239     Owner:  NLM     Status:  MEDLINE    
The transforming growth factor-beta receptor type 2 gene (TGFBR2) is mutated in most microsatellite instability-high (MSI-H) colorectal cancers. Promoter methylation of RUNX3 (runt-related transcription factor 3; encoding a transcription factor downstream of the TGF-beta pathway) is observed in colorectal cancer with CpG island methylator phenotype (CIMP), which is characterized by extensive promoter methylation and is associated with MSI-H and BRAF mutations. However, no study to date has examined interrelationship between TGFBR2 mutation, RUNX3 methylation, and CIMP in colorectal cancer. Using 144 MSI-H colorectal cancers derived from 2 large prospective cohort studies, we analyzed a mononucleotide repeat of TGFBR2 and quantified DNA methylation (by MethyLight technology) in 8 CIMP-specific promoters (RUNX3, CACNA1G [calcium channel, voltage-dependent, T type alpha-1G subunit], CDKN2A [p16], CRABP1 [cellular retinoic acid binding protein 1], IGF2 [insulin-like growth factor 2], MLH1, NEUROG1 [neurogenin 1], and SOCS1 [suppressor of cytokine signaling 1]). Among the 144 MSI-H tumors, the presence of TGFBR2 mutation (overall 72% frequency) was correlated positively with CIMP-high (with >/=6/8 methylated promoters; P < .0001), RUNX3 methylation (P = .0004), BRAF mutation (P = .0006), and right colon (P = .05); inversely with KRAS mutation (P = .006); but not significantly with sex, tumor differentiation, and p53 status (assessed by immunohistochemistry). After stratification by sex, location, tumor differentiation, RUNX3 status, KRAS/BRAF status, or p53 status, CIMP-high was persistently correlated with TGFBR2 mutation. In contrast, RUNX3, KRAS, or BRAF status was no longer correlated with TGFBR2 mutation after stratification by CIMP status. In conclusion, TGFBR2 mutation is associated with CIMP-high and indirectly with RUNX3 methylation. Our findings emphasize the importance of analyzing global epigenomic status (for which CIMP status is a surrogate marker) when correlating a single epigenetic event (eg, RUNX3 methylation) with any other molecular or clinicopathologic variables.
Shuji Ogino; Takako Kawasaki; Akiyo Ogawa; Gregory J Kirkner; Massimo Loda; Charles S Fuchs
Related Documents :
16311119 - Promoter hypermethylation profile of rassf1a, fhit, and sfrp1 in intracranial primitive...
25119239 - Construction the model on the breast cancer survival analysis use support vector machin...
11437099 - Biophenotypes and survival of brca1 and tp53 deleted breast cancer in young women.
15734999 - Deletion, methylation, and expression of the nkx3.1 suppressor gene in primary human pr...
15231689 - Aberrant methylation of the fhit gene in chronic smokers with early stage squamous cell...
12172579 - Investigation of microsatellite instability in turkish breast cancer patients.
20072669 - Protein modifications as potential biomarkers in breast cancer.
23056409 - Muc5b leads to aggressive behavior of breast cancer mcf7 cells.
22740979 - Body fluid mmp-2 as a putative biomarker in metastatic breast cancer.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2007-01-31
Journal Detail:
Title:  Human pathology     Volume:  38     ISSN:  0046-8177     ISO Abbreviation:  Hum. Pathol.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-03-19     Completed Date:  2007-05-01     Revised Date:  2012-06-21    
Medline Journal Info:
Nlm Unique ID:  9421547     Medline TA:  Hum Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  614-20     Citation Subset:  IM    
Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cohort Studies
Colorectal Neoplasms / genetics*
Core Binding Factor Alpha 3 Subunit / metabolism
CpG Islands / genetics*
DNA Methylation
Microsatellite Instability*
Polymerase Chain Reaction
Protein-Serine-Threonine Kinases
Proto-Oncogene Proteins / genetics
Proto-Oncogene Proteins B-raf / genetics
Receptors, Transforming Growth Factor beta / genetics*
ras Proteins
Grant Support
P01 CA55075-13/CA/NCI NIH HHS; P01 CA87969-03/CA/NCI NIH HHS
Reg. No./Substance:
0/Core Binding Factor Alpha 3 Subunit; 0/KRAS protein, human; 0/Proto-Oncogene Proteins; 0/Receptors, Transforming Growth Factor beta; 0/Runx3 protein, human; EC protein, human; EC Kinases; EC Proteins B-raf; EC growth factor-beta type II receptor; EC Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessment of toxicity of a glyphosate-based formulation using bacterial systems in lake water.
Next Document:  Feasibility and diagnostic agreement in teledermatopathology using a virtual slide system.